Gilead Sciences (GILD)
156.51
+3.44 (2.25%)
Upcoming Events
Latest Headlines
Gilead Sciences (GILD) PT Raised to $172 at BofA Securities
October 20, 2026 4:59 AM - StreetInsider
Gilead to present HIV and antiviral data at IDWeek 2026
October 19, 2026 8:00 AM - StreetInsider
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
October 19, 2026 8:00 AM - BizWire
Form 4 GILEAD SCIENCES, INC. For: Oct 15 Filed by: Dickinson Andrew D
October 16, 2026 4:17 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Oct 15 Filed by: Mercier Johanna
October 16, 2026 4:12 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
October 15, 2026 4:22 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
October 15, 2026 4:22 PM - SEC Filing
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
October 15, 2026 4:05 PM - BizWire
Gilead Sciences (GILD) PT Raised to $164 at BofA Securities
October 12, 2026 6:17 AM - StreetInsider
Gilead Sciences (GILD) PT Raised to $126 at RBC Capital
October 8, 2026 8:26 AM - StreetInsider
Gilead Sciences (GILD) PT Raised to $170 at JPMorgan
October 7, 2026 8:36 AM - StreetInsider
Gilead Sciences (GILD) PT Lowered to $163 at Morgan Stanley
October 7, 2026 7:58 AM - StreetInsider
Gilead Sciences (GILD) PT Raised to $158 at Truist Securities
October 7, 2026 7:13 AM - StreetInsider
Form 4 GILEAD SCIENCES, INC. For: Oct 01 Filed by: O'Day Daniel Patrick
October 2, 2026 4:40 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Sep 22 Filed by: Burkhart Erin
September 23, 2026 4:17 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Sep 15 Filed by: Dickinson Andrew D
September 16, 2026 4:31 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Sep 15 Filed by: Mercier Johanna
September 16, 2026 4:28 PM - SEC Filing
Gilead expands lenacapavir licensing to cover once-yearly HIV prevention
September 16, 2026 8:31 AM - StreetInsider
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
September 16, 2026 8:30 AM - BizWire
Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
September 15, 2026 4:21 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
September 15, 2026 4:05 PM - SEC Filing
Gilead and PAHO agree on lenacapavir HIV prevention access in Americas
September 15, 2026 11:10 AM - StreetInsider
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
September 15, 2026 11:10 AM - BizWire
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
September 15, 2026 9:00 AM - StreetInsider
Form 4 GILEAD SCIENCES, INC. For: Sep 10 Filed by: Dickinson Andrew D
September 11, 2026 6:31 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Sep 10 Filed by: Berger Dietmar
September 11, 2026 6:30 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Sep 10 Filed by: Mercier Johanna
September 11, 2026 6:29 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Sep 10 Filed by: Cain Wettan Keeley M
September 11, 2026 6:28 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Sep 10 Filed by: O'Day Daniel Patrick
September 11, 2026 6:27 PM - SEC Filing
Gilead Sciences (GILD) PT Raised to $175 at HSBC
September 10, 2026 3:28 AM - StreetInsider
Assembly Bio exercises U.S. profit-share option with Gilead for herpes program
September 8, 2026 4:00 PM - StreetInsider
Form 4 GILEAD SCIENCES, INC. For: Aug 26 Filed by: WELTERS ANTHONY
August 27, 2026 6:45 PM - SEC Filing
FDA approves Gilead's Bixlenvo HIV tablet for adults on complex regimens
August 27, 2026 5:47 PM - StreetInsider
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
August 27, 2026 5:47 PM - BizWire
Form 144 GILEAD SCIENCES, INC. Filed by: WELTERS ANTHONY
August 26, 2026 4:17 PM - SEC Filing
Form N-PX GILEAD SCIENCES, INC. For: Jun 30
August 26, 2026 4:15 PM - SEC Filing
Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
August 26, 2026 4:05 PM - BizWire
EU approves Gilead's Trodelvy combo with Keytruda for front-line TNBC
August 24, 2026 6:31 AM - StreetInsider
European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
August 24, 2026 6:31 AM - BizWire
Form 4 GILEAD SCIENCES, INC. For: Aug 20 Filed by: Bluestone Jeffrey
August 21, 2026 7:22 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Bluestone Jeffrey
August 20, 2026 4:36 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Aug 17 Filed by: Dickinson Andrew D
August 18, 2026 7:06 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Aug 17 Filed by: Mercier Johanna
August 18, 2026 6:54 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna
August 17, 2026 4:19 PM - SEC Filing
Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D
August 17, 2026 4:12 PM - SEC Filing
Form 4 GILEAD SCIENCES, INC. For: Aug 10 Filed by: Cain Wettan Keeley M
August 11, 2026 4:51 PM - SEC Filing
Morgan Stanley tracks US drug market prescriptions for week ending July 31
August 7, 2026 12:04 PM - StreetInsider
Form S-3ASR GILEAD SCIENCES, INC.
August 6, 2026 5:04 PM - SEC Filing
Form 10-Q GILEAD SCIENCES, INC. For: Jun 30
August 6, 2026 4:19 PM - SEC Filing
Gilead Sciences (GILD) PT Raised to $123 at RBC Capital
August 5, 2026 7:48 AM - StreetInsider
CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
August 4, 2026 9:41 PM - BizWire
Form 4 GILEAD SCIENCES, INC. For: Aug 03 Filed by: O'Day Daniel Patrick
August 4, 2026 5:41 PM - SEC Filing
Gilead Sciences (GILD) Tops Q2 EPS by 56c
August 4, 2026 4:33 PM - StreetInsider
Form 8-K GILEAD SCIENCES, INC. For: Aug 04
August 4, 2026 4:04 PM - SEC Filing
Gilead Sciences Announces Second Quarter 2026 Financial Results
August 4, 2026 4:01 PM - BizWire
Gilead Sciences (GILD) call put ratio 1 call to 1.1 puts into quarter results
August 4, 2026 10:46 AM - StreetInsider
Form 144 GILEAD SCIENCES, INC. Filed by: O'Day Daniel Patrick
August 3, 2026 4:42 PM - SEC Filing
Form 13F-HR GILEAD SCIENCES, INC. For: Jun 30
August 3, 2026 4:38 PM - SEC Filing
Gilead Sciences (GILD) call put ratio 3.2 calls to 1 put into quarter results
August 3, 2026 10:53 AM - StreetInsider
Gilead Sciences (GILD) call put ratio 1.8 calls to 1 put into quarter results
August 3, 2026 6:03 AM - StreetInsider
U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
August 1, 2026 10:00 AM - StreetInsider
Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Q2 Print
July 29, 2026 9:27 AM - StreetInsider
Gilead Sciences (GILD) PT Lowered to $145 at Barclays
July 29, 2026 5:19 AM - StreetInsider
Gilead Sciences (GILD) PT Lowered to $165 at Morgan Stanley
July 27, 2026 7:56 AM - StreetInsider
EU panel backs Gilead's Trodelvy plus Keytruda for breast cancer
July 24, 2026 6:26 AM - StreetInsider
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
July 24, 2026 6:26 AM - BizWire
Full Article List
